Prof. Takuya Mizuno (Yamaguchi University) in collaboration with the group of Prof. Yukinari Kato and Nippon Zenyaku Kogyo co., ltd., have developed an anti-canine CD20 antibody with exceptionally high antitumor cell activity against canine B-cell lymphoma.
This antibody drug not only exhibits significantly higher in vitro killing activity against tumor cells than previously reported anti-canine CD20 chimeric antibodies, but also demonstrated tumor growth suppression in mice implanted with canine tumors. Furthermore, in safety studies using healthy Beagle dogs, the antibody demonstrated such potent activity that normal B cells expressing the target CD20 molecule were reduced to nearly zero by the day after administration. This suggests the antibody possesses similar killing capacity against B-cell lymphomas expressing the CD20 molecule, indicating potential for clinical efficacy.
The results were published in Scientific Reports on July 10, 2020.
Related materials
Tohoku University press release page (Japanese) (click here)